← Back to Patent Explorer
US4146640A Expired / Lapsed US ⏱️ 0.0 years remaining

Complement inhibitors

Assignee: Wyeth Holdings LLC
•
Filing: 1978-02-06
•
Granted: 1979-03-27
•
Expires: 1998-02-06
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Certain C-substituted trisulfonic acids, acid ureides, oxalyl amides and salts thereof useful as complement inhibitors.

Inventors

  • 👤 Robert H. Lenhard
  • 👤 Seymour Bernstein

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 21:44
CPC Classifications
C; C07; C07C; C07C303/00; C07C303/32; A; A61; A61K; A61K31/00; A61K31/185; Y; Y10; Y10S; Y10S436/00; Y10S436/821

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 58 words
A method of inhibiting the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement inhibiting amount of a compound of the formula: ##STR13## wherein R is ##STR14## and A is hydrogen, alkali metal or alkaline earth, with the proviso that each A is identical in the same compound.
Claim 2
Independent Claim 58 words
A method of inhibiting the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement inhibiting amount of a compound of the formula: ##STR13## wherein R is ##STR14## and A is hydrogen, alkali metal or alkaline earth, with the proviso that each A is identical in the same compound.
Claim 3
Independent Claim 37 words
A method of inhibiting the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement inhibiting amount of a compound of the formula: ##STR15## wherein R is ##STR16##
Claim 4
Independent Claim 37 words
A method of inhibiting the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement inhibiting amount of a compound of the formula: ##STR15## wherein R is ##STR16##
Claim 5
Dependent Claim 14 words
A method according to claim 2 wherein the compound is 8,8'-{oxalylbis{{[imino(4-methyl-1,3-phenylene)]carbonyl}imino}}di-1,3,6-naphthalenetrisulfonic acid, hexasodium salt.
Claim 6
Independent Claim 57 words
A method of inhibiting the complement system in a warm-blooded animal which comprises internally administering to said animal an effective complement inhibiting amount of a pharmaceutically acceptable compound of the formula ##STR17## wherein R is ##STR18## and A is hydrogen, alkali metal or alkaline earth, with the proviso that each A is identical in the same compound.
Claim 7
Independent Claim 57 words
A method of inhibiting the complement system in a warm-blooded animal which comprises internally administering to said animal an effective complement inhibiting amount of a pharmaceutically acceptable compound of the formula ##STR17## wherein R is ##STR18## and A is hydrogen, alkali metal or alkaline earth, with the proviso that each A is identical in the same compound.
Claim 8
Independent Claim 36 words
A method of inhibiting the complement system in a warm-blooded animal which comprises internally administering to said animal an effective complement inhibiting amount of a pharmaceutically acceptable compound of the formulae ##STR19## wherein R is ##STR20##
Claim 9
Independent Claim 36 words
A method of inhibiting the complement system in a warm-blooded animal which comprises internally administering to said animal an effective complement inhibiting amount of a pharmaceutically acceptable compound of the formulae ##STR19## wherein R is ##STR20##
Claim 10
Dependent Claim 14 words
A method according to claim 5 wherein the compound is 8,8'-{oxalylbis{{[imino(4-methyl-1,3-phenylene)]carbonyl}imino}}di-1,3,6-naphthalenetrisulfonic acid, hexasodium salt.
Claim 11
Dependent Claim 12 words
A method according to claim 5 wherein the compound is administered intra-articularly.

References Cited (Backward Citations)

US3897434A Cited
US3903106A Cited
US4027038A Cited
US4046805A Cited
US4051176A Cited
US4087548A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1982-03-26 1982-09-25 1983-03-27 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1986-03-26 1986-09-25 1987-03-27 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1990-03-26 1990-09-25 1991-03-27 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag